Literature DB >> 15269823

Heparin binding protein is increased in chronic leg ulcer fluid and released from granulocytes by secreted products of Pseudomonas aeruginosa.

Katarina Lundqvist1, Heiko Herwald, Andreas Sonesson, Artur Schmidtchen.   

Abstract

Recently it was demonstrated by Gautam, et al. that release of neutrophil-borne heparin-binding protein (HBP), also known as CAP37/azurocidin, induced endothelial hyperpermeability and neutrophil efflux. Here, we show that chronic leg ulcer fluid, in contrast to wound fluid from acute wounds, contains highly increased levels of HBP. Immunohistochemistry demonstrated the presence of HBP in chronic ulcer tissues. Furthermore, secreted products of Pseudomonas aeruginosa were found to induce release of HBP from human neutrophils. Our data suggest a possible link between bacterial presence and HBP-release in chronic ulcers. Thus, targeting HBP offers an interesting option for reduction of endothelial barrier dysfunction in chronic ulcers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269823     DOI: 10.1160/TH03-12-0732

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Proteolytic activation transforms heparin cofactor II into a host defense molecule.

Authors:  Martina Kalle; Praveen Papareddy; Gopinath Kasetty; Douglas M Tollefsen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

2.  C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules.

Authors:  Praveen Papareddy; Martina Kalle; Gopinath Kasetty; Matthias Mörgelin; Victoria Rydengård; Barbara Albiger; Katarina Lundqvist; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

3.  Antimicrobial effects of helix D-derived peptides of human antithrombin III.

Authors:  Praveen Papareddy; Martina Kalle; Ravi K V Bhongir; Matthias Mörgelin; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

4.  Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism.

Authors:  Jitka Petrlova; Finja C Hansen; Mariena J A van der Plas; Roland G Huber; Matthias Mörgelin; Martin Malmsten; Peter J Bond; Artur Schmidtchen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-04       Impact factor: 11.205

5.  The contact system--a novel branch of innate immunity generating antibacterial peptides.

Authors:  Inga-Maria Frick; Per Akesson; Heiko Herwald; Matthias Mörgelin; Martin Malmsten; Dorit K Nägler; Lars Björck
Journal:  EMBO J       Date:  2006-11-09       Impact factor: 11.598

6.  Proteolysis of human thrombin generates novel host defense peptides.

Authors:  Praveen Papareddy; Victoria Rydengård; Mukesh Pasupuleti; Björn Walse; Matthias Mörgelin; Anna Chalupka; Martin Malmsten; Artur Schmidtchen
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

7.  Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation.

Authors:  Andreas Ambrosch; Ralf Lobmann; Andreas Pott; Jŭrgen Preissler
Journal:  Int Wound J       Date:  2008-01-03       Impact factor: 3.315

Review 8.  A Promising Candidate: Heparin-Binding Protein Steps onto the Stage of Sepsis Prediction.

Authors:  Yang Yang; Guihuan Liu; Qingnan He; Jie Shen; Linyong Xu; Ping Zhu; Mingyi Zhao
Journal:  J Immunol Res       Date:  2019-12-16       Impact factor: 4.818

Review 9.  Wound fluid sampling methods for proteomic studies: A scoping review.

Authors:  Joe Harvey; Kieran T Mellody; Nicky Cullum; Rachel E B Watson; Jo Dumville
Journal:  Wound Repair Regen       Date:  2022-04-05       Impact factor: 3.401

10.  Protein C inhibitor--a novel antimicrobial agent.

Authors:  Erik Malmström; Matthias Mörgelin; Martin Malmsten; Linda Johansson; Anna Norrby-Teglund; Oonagh Shannon; Artur Schmidtchen; Joost C M Meijers; Heiko Herwald
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.